PERANAN MARKER JANTUNG SEBAGAI PENANDA KEBERHASILAN TERAPI GAGAL JANTUNG AKUT

Prima Ursila, Muhammad Stukri

Abstract


Acute heart failure is a term used to describe the condition of heart failure with acute onset and worsening of symptoms and signs of heart failure. Acute heart failure is associated with decreased survival and high rehospitalization. In addition to routine clinical laboratory tests, a number of biomarkers have received recommendation helping in prognostic acute heart failure. Biomarkers must have underlying pathophysiological relevance, and if the prognostic should be used both to initiate certain therapies and monitors during the therapy of acute heart failure.

Keywords


acute heart failure, biomarker, therapy

Full Text:

PDF

References


Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC Guidelines for The Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal. 2016;1-85.

Mc Murray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal, 2012;14:803–869.

Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure. A Scientific Statement from the American Heart Association. Circulation. 2017;135:e1054–e1091.

O’Connor CM, Abraham WT, Albert NM, Gattis SW, Gheorghiade M, Greenberg BH, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008;156:662–673.

Iqbal N, Wentworth B, Choudhary R, Landa AD, Kipper B, Fard A, et al. Cardiac biomarkers: new tools for heart failure management. Cardiovasc Diagn Ther 2012;2(2):147-164.

Maisel AS. Biomonitoring and Biomarker-Guided Therapy. Journal of the American College of Cardiology. 2011; 1890-1892.

Wattersten N, Maisel AS. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure A Scientific Statement From AHA. The American Journal of Medicine 2016;129,560-567.

Kim H, Januzzi JL. Peptida natriuresis testing in heart failure. Circ-AHA Journal 2011;123:2015-2017.

Tubaro M, Vranckx P, Price S, Vrints C. The ESC Textbook of Intensive and Acute Cardiovascular Care. 2015;1-33.

Kim H. Cardiac Biomarkers and Heart Failure. American Journal of Cardiology. 2015.

Dhaliwal AS, Deswal A, Pritchett A, Aguilar D, Kar B, Souchek J, et al. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009;15:293–299.

Troughton R, Felker GM, Januzzi JL Jr. Peptida natriuresis-guided heart failure management. European Heart Journal. 2014;35:16–24

Di Somma S, Magrini L, Pittoni V, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care. 2010;14:R116.

Roland R.J, van Kimmenade, James L, et al. Emerging Biomarkers in Heart Failure. American Association for Clinical Chemistry. 2012;58:1 127–138.

Di Somma S, Magrini L, Pittoni V, Marino R, Mastrantuono A, Ferri E, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute HF: the Italian RED Study. Crit Care 2010;14:R116.

James L. Januzzi, Jr, MD, Troughton R. Serial peptida natriuresis measurements are useful in heart failure management. Circulation. 2013;127:500-508.

Porapakkham P, Zimmet H, Billah B, Krum H. BNP-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170:507–514.

Boer RA, Daniels LB, Maisel A. State of the Art: Newer biomarkers in heart failure. European Journal of Heart Failure. 2015;17,559–569.

Januzzi JL Jr, Filippatos G, Nieminen M, Gheoghiade M. Troponin elevation in patients with heart failure. Eur Heart J. 2012;33(18):2265-2271.

Yancy CW, Jessup M, Bozkurt B, Butler J, Case DE, Dazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2013;62(16):e147-e239.

Wu AB. Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy. Curr Heart Fail Rep. 2013;10:434–440.

Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. European Journal of Heart Failure. 2015;17,1262–1270.

Ferreira JP, Santos M, Almeida S. High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients. Cardiology Research and Practice. 2014.

Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52(18):1458-1465.




DOI: http://dx.doi.org/10.32883/hcj.v5i4.850

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 HUMAN CARE JOURNAL
Published by Universitas Fort De Kock, Bukittinggi, Indonesia
© Human Care Journal  e-ISSN : 2528-665X P-ISSN : 2685-5798

View Human Care Journal Stats